AB1630 RISK FACTORS FOR CARDIAC INVOLVEMENT IN IDIOPATHIC INFLAMMATORY MYOPATHIES

Background Idiopathic inflammatory myopathies (IIMs) are heterogenous systemic autoimmune disorders that mainly affect the skin, muscles, and lungs. Whereas cardiac involvement is considered to be rare, it causes inflammation fibrosis leading severe morbidity mortality. However, little known about clinical characteristics risk factors for in patients with IIMs. Objectives The aim of this study was clarify frequency its Methods We retrospectively reviewed consecutive IIMs who visited Keio University Hospital from 2002 2022. divided into two groups according presence or absence symptomatic compared their autoantibodies between groups. defined as chest pain, palpitation, cardiogenic leg edema, respiratory distress accompanied by abnormal findings examinations such electrocardiography, echocardiography, and/or magnetic resonance imaging (MRI). Results included 145 analysis. mean age at diagnosis 55 years old, 71.7% were female. Forty (27.6%) polymyositis, 53 (36.6%) dermatomyositis, 44 (30.3%) amyopathic 8 (5.5%) immune-mediated necrotizing myopathy. Among them, 52 (35.9%) had on MRI, 17 (11.7%) diagnosed 65 during observation period 20.0 years. Comparison identified no difference age, sex distribution, duration IIM Also, significant found positivity anti-amynoacyl tRNA synthetase antibody, anti-MDA5 anti-SS-A subtypes, skin rash, malignancy, interstitial lung disease, history cyclophosphamide use, maximum levels CK, aldolase, CK-MB, troponin T, CRP. Raynaud’s phenomenon neutrophil/lymphocyte ratio significantly higher involved group non-cardiac (53.85% vs 15.24%, p=0.0009; 56.25% 18.25%, p=0.0006). Multivariable analysis (odds [OR] 8.42, 95% confidence interval [CI] 2.10-33.8, p=0.0026) elevated (OR 6.92, CI 1.73-27.6, p=0.0061) independent involvement. One patient died failure period. Conclusion Abnormal frequent Evaluating important, especially diagnosis. Reference [1]Lilleker JB, Vencovsky J, Wang G, et al. EuroMyositis registry: an international collaborative tool facilitate myositis research. Ann Rheum Dis. 2018;77: 30–39. Figure 1. Risk Acknowledgements: NIL. Disclosure Interests None Declared.